0
Signin
countryflagUS

18889881171

AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

Eliem Therapeutics Inc

Healthcare US ELYM

7.835USD
-0.155(1.94%)

Last update at 2024-05-16T16:51:00Z

Day Range

7.678.99
LowHigh

52 Week Range

2.214.75
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -45.24400M -47.48000M -20.66800M -6.54700M
Minority interest - - - -
Net income -45.35300M -47.48000M -11.51000M -3.79700M
Selling general administrative 18.92M 12.35M 2.42M 0.68M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - - - -
Ebit -45.13500M -35.67200M -20.92500M -7.44600M
Ebitda -43.65100M -35.50200M -2.86600M -1.93100M
Depreciation and amortization 1.48M 0.17M 18.06M 5.51M
Non operating income net other -0.10900M -11.80800M - -
Operating income -45.13500M -35.67200M -20.92500M -7.44600M
Other operating expenses 45.13M 35.67M 11.77M 4.70M
Interest expense 1.59M 11.61M 0.00000M 0.00000M
Tax provision - - - -
Interest income - - - -
Net interest income - - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.11M 11.81M -9.15800M -2.75000M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 45.13M 35.67M 11.77M 4.70M
Cost of revenue - - - -
Total other income expense net -0.10900M -11.80800M 0.26M 0.90M
Discontinued operations - - - -
Net income from continuing ops -45.24400M -95.08300M -20.66800M -6.54700M
Net income applicable to common shares -45.24400M -52.02800M -22.95300M -7.39100M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 134.99M 173.24M 24.63M 21.39M
Intangible assets - - - -
Earning assets - - - -
Other current assets 10.83M 0.85M 0.01M 0.04M
Total liab 6.28M 6.04M 3.06M 0.78M
Total stockholder equity 128.72M 167.20M 21.57M 20.61M
Deferred long term liab - - - -
Other current liab 5.05M 4.63M 1.98M 0.14M
Common stock 0.00300M 0.00300M 0.00100M 0.00100M
Capital stock 0.00300M 0.00300M 46.55M 26.18M
Retained earnings -120.86000M -75.61600M -28.13600M -7.46800M
Other liab - 0.00700M - -
Good will - - - -
Other assets 0.13M 0.07M 2.63M 0.11M
Cash 43.59M 46.92M 20.49M 21.22M
Cash and equivalents - - - -
Total current liabilities 6.10M 6.03M 3.06M 0.78M
Current deferred revenue - - - -
Net debt -43.10500M -46.92200M -20.48700M -21.22300M
Short term debt 0.30M - - -
Short long term debt - - - -
Short long term debt total 0.48M - - -
Other stockholder equity 249.93M 69.70M 3.15M 1.91M
Property plant equipment 0.47M - - -
Total current assets 134.39M 148.25M 22.00M 21.28M
Long term investments 0.00000M 24.92M - -
Net tangible assets 128.72M 167.20M -24.98300M -5.56200M
Short term investments 79.98M 89.56M - -
Net receivables 6.49M 6.52M - -
Long term debt - - - -
Inventory -6.49200M 4.40M - -
Accounts payable 0.75M 1.40M 1.09M 0.65M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.35800M -0.12300M - -
Additional paid in capital - - - -
Common stock total equity 0.00300M 0.00300M 0.00100M 0.00100M
Preferred stock total equity - - - -
Retained earnings total equity -120.86000M -75.61600M - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.13M 0.07M 2.63M 0.11M
Deferred long term asset charges - - - -
Non current assets total 0.60M 24.99M 2.63M 0.11M
Capital lease obligations 0.48M - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 34.44M -114.97000M 8.08M -114.97000M
Change to liabilities -0.22800M 3.69M -0.02400M 0.02M
Total cashflows from investing activities 34.44M -114.97000M 8.08M 8.08M
Net borrowings - - - -
Total cash from financing activities 0.00000M 177.23M 4.92M 26.24M
Change to operating activities 0.86M -4.32200M -2.91200M -0.32600M
Net income -45.24400M -47.48000M -20.66800M -6.54700M
Change in cash -3.33700M 26.43M -0.73600M 21.22M
Begin period cash flow 46.92M 20.49M 21.22M 0.00000M
End period cash flow 43.59M 46.92M 20.49M 21.22M
Total cash from operating activities -37.36900M -36.07200M -14.09800M -5.00800M
Issuance of capital stock 0.00000M 177.08M 4.92M 26.24M
Depreciation -0.17700M 1.84M - -
Other cashflows from investing activities - - - -
Dividends paid - 4.55M - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - 0.15M - -
Other cashflows from financing activities 34.44M 94.09M 8.08M 26.24M
Change to netincome 7.40M 3.98M 9.51M 1.85M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating 0.88M -4.18900M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -2.92900M 26.19M - -
Change in working capital 0.21M -4.17200M -2.93600M -0.30900M
Stock based compensation 6.99M 3.74M 0.71M 0.00000M
Other non cash items 2.06M 11.84M 8.80M 1.85M
Free cash flow -37.36900M -36.07200M -14.09800M -5.00800M

Fundamentals

  • Previous Close 7.99
  • Market Cap76.10M
  • Volume77457
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.46

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ELYM
Eliem Therapeutics Inc		 -0.155 1.94% 7.83 - - - 0.69 0.69
NVO
Novo Nordisk A/S		 -1.63 1.21% 133.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.57 0.43% 132.69 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.20 0.27% 438.69 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.03 1.09% 96.00 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

Eliem Therapeutics Inc

23515 NE Novelty Hill Road, Redmond, WA, United States, 98053

Key Executives

Name Title Year Born
Mr. Robert W. Azelby M.B.A. Pres, CEO & Director 1968
Ms. Erin M. Lavelle Exec. VP, COO & CFO 1977
Dr. Valerie Morisset Ph.D. Chief Scientific Officer and Exec. VP of R&D 1970
Mr. James B. Bucher J.D. Exec. VP, Gen. Counsel & Sec. 1966
Ms. Jo Palmer-Phillips Ph.D. Chief Devel. Officer NA
Dr. Mark Versavel M.B.A., M.D., MBA, Ph.D. Interim Chief Medical Officer 1959
Ms. Susan Franks M.S. Sr. VP & Head of Regulatory Affairs NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).